Ciloa technology


A unique technology that makes it possible to produce any types of membrane proteins (GPCRs, kinase receptors, ion channels, viral proteins...) with their fully native conformations on exosomes outside the cell.

Breakthrough exosome solution

Ciloa offers research organizations and biotechnology companies its patented technology. The patents is based on the discovery of an exosomal signal peptide that contains motifs likely to interact with the so-called ESCRT proteins.

Merging the exosomal signal peptide with a membrane protein triggers its active sorting and secretion with exosomes. Ciloa succeeds in the challenge of actively connecting two natural cellular pathways:

  • The ER/Golgi pathway that enables the synthesis, the proper folding, the oligomerisation and the post-translational modifications of membrane proteins.
  • A specific sorting pathway that allows the secretion, outside cells, of membrane proteins embedded in the membranes of natural nanovesicles called exosomes.

Because it uses entirely natural pathways, the Ciloa technological platform makes it possible to produce membrane proteins with the true native conformations in a concentrated form outside the cell. More, several proteins can be targeted to the same exosomes, allowing the production of exosomes harboring homo- or hetero-oligomers and reconstitution of membrane protein complexes out of cells.

 Ciloa membrane proteins

Ciloa has produced more than 50 membrane proteins of any types (GPCRs, kinase receptors, transporters, ion channels, viral membrane proteins...) on natural nanovesicles, (exosomes). Of which, more than 20 GPCRs, viral envelope protein multimers and hetero-oligomers of ion channel complexes made of alpha and beta chains.

The core know-how of Ciloa technology to successfully combine these two pathways was elaborated in an academic laboratory, and is protected by CNRS and University of Montpellier II patents.